This secondary analysis of the Stockholm tamoxifen clinical trial examines the association of clinical breast cancer markers with 25-year survival and tamoxifen treatment benefit among postmenopausal women with lymph node–negative ER-positive/ERBB2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.